Drug intelligence / Profile preview

CBM-401

Development stage: Preclinical
Lead developer: Cellion BioMed
Modality: Small Molecules

Overview

CBM-401 is a small molecule inhibitor of the KCa3.1 channel (intermediate conductance calcium-activated potassium channel) currently in preclinical development by Cellion BioMed for the treatment of hypertrophic scars. The drug belongs to the CBM-Nx/Fx series and functions by modulating KCa3.1 activity to increase local concentrations of adenosine and cyclic adenosine monophosphate (cAMP). This signaling cascade results in potent anti-fibrotic, anti-inflammatory, and antioxidant effects, which are intended to mitigate the excessive tissue growth and inflammation associated with scar formation. Cellion BioMed is developing this candidate in partnership with KINS.

Targets

KCNN4 (Intermediate conductance calcium-activated potassium channel protein 4)

Beyond the preview

Go deeper on CBM-401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBM-401.

Explore the full profile